Open an account

Akari Therapeutics

AKTX · NASDAQ

$9.29−$0.60 (−6.07%)TodayMarket closed ·
Prev close $9.89

About AKTX

Akari Therapeutics Plc is a clinical-stage biopharmaceutical company, which engages in the development and commercialization of therapeutics to treat orphan autoimmune and inflammatory diseases. The company is headquartered in Tampa, Florida and currently employs 5 full-time employees. The company went IPO on 2014-01-31. Utilizing its ADC discovery platform, it generates bifunctional ADC candidates and optimizes them based on the desired application to target a range of cancers. Its lead candidate, AKTX-101, targets the TROP2 receptor on cancer cells, and with a proprietary linker, delivers its novel PH1 payload directly into the tumor. PH1 is a novel bifunctional payload that is designed to disrupt RNA splicing within cancer cells, inducing tumor-specific cell death while generating immunostimulatory effects and minimizing off-target toxicity. Its pipeline includes AKTX-101 and AKTX-102, a discovery-stage ADC that pairs PH1 with an undisclosed target antibody. The company is pursuing research on two additional novel payloads, such as PH5 and PH6. The company also has an ADC Platform for oncology and PHP-303 program for genetic disease, liver disease and inflammation.

Employees
5
Headquarters
Tampa, Florida
Listed
Jan 31, 2014
Sector
Health Care
Industry
Biotechnology
Website
akaritx.com

AKTX key statistics

Market cap
17.31M
Price-earnings ratio
0.00
Dividend yield
—
Average volume
48.32K
Volume
35.12K
Open price
$9.14
High today
$9.72
Low today
$9.15
52 Week high
$33.60
52 Week low
$3.02

Akari Therapeutics (AKTX) at a glance

As of Oct 20, 2026, Akari Therapeutics (AKTX) shares are priced at $9.29, giving the company a market cap of 17.31M and a price-to-earnings ratio of 0.00.

Today the stock has traded between $9.15 and $9.72. The current price is 1.5% above the day's low and 4.5% below its high.

Volume so far is 35.12K shares, below the average of 48.32K shares a day.

Over the past year Akari Therapeutics has ranged from $3.02 to $33.60, and now sits 21% of the way up that range.

Akari Therapeutics met or beat analyst EPS estimates in 4 of the last 8 quarters. In Q2 FY26 it reported -$2.68 per share against an estimate of -$1.31.

The average analyst price target is $29.71, 219.8% above the current price, from 3 recent ratings.

Analyst ratings

Latest rating from each analyst over the past 12 months

100%of 3 analyst ratings say Buy
  • Buy100.0%
  • Hold0.0%
  • Sell0.0%
Price target · 6 analystsAvg $29.71
Low
$19.69
Now
$9.29
High
$42.00

AKTX earnings

Earnings per share, reported against the analyst estimate

Beat the estimate in 3 of the last 8 quarters, by 100.0% on average.

  1. Q4 FY19: reported -$312.00 per share against an estimate of -$118.32
  2. Q1 FY20: reported -$104.00 per share against an estimate of $0.00
  3. Q1 FY21: reported $0.00 per share against an estimate of $0.00
  4. Q2 FY25: reported $0.00 per share against an estimate of -$4.69
  5. Q3 FY25: reported $0.00 per share against an estimate of -$3.13
  6. Q4 FY25: reported $0.00 per share against an estimate of -$1.53
  7. Q1 FY26: reported -$1.57 per share against an estimate of -$1.40
  8. Q2 FY26: reported -$2.68 per share against an estimate of -$1.31

AKTX news

  • Vandana Singh

    Akari Targets Mid-2027 for Human Trial of Differentiated Cancer Therapy

  • 12 Health Care Stocks Moving In Friday's After-Market Session

  • Avi Kapoor

    Crude Oil Edges Higher; US Consumer Sentiment Falls In May

  • Evette Mitkov

    Akari Therapeutics Stock Jumps On Promising Preclinical Data

  • Avi Kapoor

    Dow Jumps 250 Points; BJ's Wholesale Shares Fall After Q1 Results

  • 12 Health Care Stocks Moving In Thursday's After-Market Session

  • 12 Health Care Stocks Moving In Tuesday's After-Market Session

  • 12 Health Care Stocks Moving In Tuesday's Intraday Session

Similar companies

Companies in the same industry as Akari Therapeutics

Most active stocks

Highest trading volume today

Newly listed

Companies that went public in the past six weeks

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.